Scientific edence suggests that humans and wildlife speces may experience adverse health consequences from exposure to environmental chemicals that interact with the endocrine system. Reliable short-term assays are needed to identifr hormone-dismpting chemicals. In this study we demonstrate that the estrogenic activity of a chemical can be evaluated by assaying induction or repression of endogenous estrogen-regulated 'marker genes" in human breast cancer MCF-7 cells. We induded four marker genes in the assay -pS2, transforming growth factor P3 (TGa933), monoamine oxidase A, and ecl-antichymotrypsin-and we evaluated estrogeniic acivity for 17P-estradiol (E2), diethylstilbestrol, ci-zearalanol, nonylphenol, genistein, methoxychlor, endosulphan, o,p-DDE, bisphenol A, dibutylphthalate, 4-hydoxy tamoxifn, and ICI 182.780. All four marker genes responded strongly to the three high-potency estrogens (E29diethylstilbestol, and -earalanol), whereas the potency of the other chemicals was 103-to 106-fold lower than that of E2. There were some maker gene-dependent differences in the relative potencies of the tested chemicals. TG$P3 was equally sensitive to the three high-potency estrogens, whereas the sensitivity to oc-zearalanol was approximately 10-fold lower than the sensitivity to E2 and diethyistilbestrol when assayed with the other three marker genes. TIhe potency of nonylphenol was equal to that of genistein when assayed with pS2 and TG1f3, but 10-to 100-fold higherilower with monoamine oxidase A and al-antichymotypsin, respectively. The results are in agreement with results obtained by other methods and suggest that an assay based on endogenous gene expression may offer an attractive alternative to other E-SCREEN methods.
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The presence of endocrine disruptors in our environment has caused an increasing concern of their possible impact on wildlife and human health (1, 2) . Investigators have focused on a possible decrease in human semen quality and an undisputed increased incidence of testicular cancer over the past few decades (3, 4) . Although hypothetical, these changes may be caused by intrauterine exposure of the male fetus to estrogens or antiandrogens (5) . In addition, significant increases in the incidences of prostate, endometrium, and breast cancer, and malformations of the external and internal genitals have been observed over the past 40-50 years, and may also be associated with increased exposure to estrogens (6a-8.
Environmental estrogens indude a variety of very different chemicals such as polychlorinated biphenyls (PCBs), organochlorine pesticides, alkylphenols, phthalates, and food antioxidants (2, (9) (10) (11) . In addition, many plants and fungi contain compounds with estrogenic activity-the phytoestrogens and mycoestrogens (2) . The (12. According to the EDSTP, the compounds will be tested for effects on the estrogen, androgen, and thyroid systems in humans, fish, and wildlife by a combination of in vitro and in vivo screening assays. The assays proposed by the EPA to detect estrogenic chemicals indude estrogen receptor (ER) binding assays (13, 14) , transcriptional activation assays (15) , rodent 3-day uterotrophic assays (16) , rodent 20-day pubertal female assays (1;), and the fish gonadal recrudence assay (18) . For chemicals that are positive in the screening, this will be followed by longer-term studies to determine whether the chemicals cause adverse effects in humans, fish, and wildlife and to establish a quantitative relationship between the dose and the adverse effect.
Short-term estrogenicity assays in the EDSTP. The validity and usefulness of some of the assays included in the EDSTP and other short-term estrogenicity assays was recently evaluated in a comparison study by Andersen et al. ( 1) .
The in vitro assays are based either on measurement of direct binding to isolated receptors or on the induction of a reporter gene regulated through the ER. ER binding assays involve the competition of the test compound with radiolabeled estradiol for specific binding to the ER in whole cells or in cell homogenates (13, 14) . Alternatively, specific binding to isolated recombinant receptors could be measured (19, 20) . The direct binding assay can easily be automated and thus scaled to accommodate testing of a large number of compounds. However, the ER binding assay only shows how well the tested compound binds to the ER, but it does not define the ligand as an agonist or antagonist. Furthermore, chemicals that are metabolized to estrogenic compounds in mammalian cells are not detected in the cell free binding assays.
In reporter gene-based assays, yeast or mammalian cells are transfected with the human ER and a reporter gene, such asgalactosidase or luciferase, under the control of an estrogen responsive promoter. The activity of the reporter gene is directly related to the transcriptional activation activity of the test compound (15) . The yeast-based reporter gene assays can easily be automated, but they do not discriminate between estrogenic and antiestrogenic chemicals (19, 20) . Mammalian reporter gene assays are under development, and they may eventually replace the current yeast-based assays (21) (22) (23) .
In the rodent 3-day uterotrophic assay, estrogenicity is estimated as an increase in uterine tissue mass in ovariectomized or immature rodents after 3 days of treatment (16) ; in the rodent 20-day pubertal female assay, estrogenicity is indicated by accelerated vaginal opening in weanling rats after daily treatment beginning at 21 days of age (17) .
Another commonly used in vivo estrogenicity assay measures the level of the yolk protein vitellogenin in male fish, which is very low in male fish but increases in a dose-dependent manner after exposure to estrogenic compounds (18) ; this is one of the primary end points in the fish gonadal recrudescence assay. The in vivo assays have several advantages, especially the following: they take into concideration the effects of metabolism, plasma-protein binding, and pharmacokinetics; and they typically cover a broader range of mechanisms of actions than in vitro assays. Because of their cost, complexity, and ethical concerns, however, animal models are not suited for large-scale screening of chemicals.
Currently used alternative assays. There are several attractive short-term assays that are not included in the EDSTP, including the cell proliferation assay (E-SCREEN) described by Soto et al. (9) . The E-SCREEN assay is based on the dose-response relationship between the proliferation of human estrogen-dependent breast cancer cells and the concentration of estrogen to which the cells are exposed during 6 days of incubation (9) . The sensitivity of the E-SCREEN assay is relatively high, and it can discriminate between estrogen agonists and antagonists. However, the proliferative response is an indirect effect, and the assay is complicated by the toxicity of some compounds. Also, it is undear to what degree proestrogens may, or may not, be activated to their estrogenic form in cultured cells.
In a clinical setting, the radioimmunoassay (RIA) is commonly used to measure serum estradiol concentrations. Because it is antibody-based, the RIA can only measure 17,B-estradiol (E2), although similar assays probably could be developed for other compounds. However, RIA assays have a detection limit of [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] pmol/L and cannot be used to measure, for example, the concentration of estadiol in the serum of prepubertal children (24) .
Recently, Nishikawa et al. (25) proposed an assay based on yeast two-hybrid measurements of protein-protein interactions between ER and coactivators. Because estrogen agonist binding leads to the dissociation of corepressors and recruitment of coactivators, this assay measures both the ability of a compound to bind to the receptor and whether it recruits coactivators; therefore, it yields more information than a simple binding assay. Furthermore, other protein-protein interactions could be included: for example, interactions with corepressors could discriminate between agonists and antagonists because antagonists generally do not displace corepressors.
The sensitivity of the currently available assays, measured as the lowest detectable concentration of estradiol, is very different. The most sensitive is the MCF-7 cell proliferation assay, in which concentrations as low as 0.1 pM can be measured (9) ; this assay may actually be able to measure concentrations in the femtomolar range (26) . The yeast-based reporter gene assays are generally several orders of magnitude less sensitive (27) , although measurements of very low estradiol concentrations have been reported (15) . The fish vitellogenin assay can detect estradiol at approximately 4 pM (18), whereas direct binding assays generally require concentrations in the nanomolar range (19, 28) .
Thus, there is a need for additional very sensitive assays that can be used to verify results obtained by, for example, MCF-7 cell proliferation assays.
Assaying the expression levels ofendogenous genes. An alternative assay could be based on quantitation of estrogen-induced changes in the expression levels of endogenous genes, either in cultured cells or in selected tissues from exposed animals. For example, Petit et In the end, all the end points currently used to determine estrogenicity in animals (and cells) are derived from changes in gene expression, and these changes in the expression of endogenous genes could be as good an end point as, for example, increased uterine weight, provided the responsible genes have been identified.
In this study we show that a cell-based endogenous gene expression assay is very sensitive and that it can be used to assay the estrogenicity of different putative estrogenic chemicals (Figure 1 ). Estrogenicity is evaluated as induction or repression of four endogenous estrogen-regulated "marker genes" selected from a collection of previously identified estrogen-regulated genes. buffer (8% ficoll 400, 10 mM EDTA, 10 mM NaOH, 0.1225% bromophenol blue, and 0.1225% xylene cyanol in formamide) was added and the samples were denatured for 2 min at 96°C. Samples were then loaded onto a 5% polyacrylamide "sequencing type" gel run on the ALF-Express sequenator (Amersham Pharmacia Biotech). After electrophoresis at 25 W for 3 hr, gels were transferred to Whatmann 3 MM paper (Whatmann, Maidstone, UK), dried, and analyzed by autoradiography and phosphor imaging.
Amplification of cDNA fragments from differential display gels. We excised differentially expressed bands from the dried gels and recovered the DNA content by shaking the sample in 50 pL Te buffer (10 mM Tris-HCI, pH 7.5; 0.1 mM EDTA) at 95°C for 15 min.
We used 5 pL for PCR amplification in a total volume of 27 pL (final concentrations) 10 mM Tris-HCl, pH 8.3; 50 mM KCI; 1.8 mM MgCl2; 0.1% Triton X-100; 0.005% gelatin; 70 pM each dATP, dCTP, dGTP, and dTTP; 2.5 U AmpliTaq (Perkin-Elmer); 10 pmol upstream primer; and 10 pmol "extended" downstream primer (T7HT1 1V; Table 1 ). Cycle conditions were as described (35) . Some of these are listed in Table 2 together with their corresponding accession numbers, upstream primer sequences, and the size and regulation of the bands. Because most primer combinations result in the display of 100-150 bands, the expression levels of40,000-60,000 bands have been investigated. Comparing this with the 20,000-30,000 genes which are expressed in a human cell at a given time (36) Optimization ofPCR. For the 20 originally selected genes, we improved the PCR by optimizing the matches between primers and mRNA because there were several mismatches in the alignment of the random upstream primer sequences used in the screening and the mRNA sequences. We designed the targeted upstream primers by correcting the mismatches and extending the primer with four to five extra nudeotides at the 5' end. Thus, combining the targeted upstream primer with the appropriate downstream primer results in a band of the same size as in the screening (31) . Because the primer position is important for the efficiency of PCR amplification, several targeted primers were tested for each gene, and the primer that resulted in the strongest band was selected for further testing.
In most cases, the use of targeted primers significantly increased the sensitivity of the assay. For example, with a random upstream primer that contained three mismatches within the 3'-six nucleotides of the primer, a concentration of 10-10 M E2 was required to induce a detectable increase in the expression of pS2 ( Figure 3A) , whereas application of a targeted upstream primer reduced the required concentration to only 10-12 M ( Figure 3B) .
To further enhance the assay, it can be an advantage to reduce the number of competing bands, which can be done by replacing the one-base-anchored downstream primer (HT1 1V; Table 1 ) with a two-base-anchored primer (HTI IVN; Table 1 ). In this study, we used two-base-anchored downstream primers for TGF13 and MAO-A.
Rapid induction of marker genes by EZ
The observed changes in gene expression could, in principle, be caused by the activation or repression of other genes, for example, a transcription factor that is directly regulated by estrogen. The expression profiles of genes directly regulated by estrogens suggest that primary effects of estrogen are induced within a few hours, whereas secondary effects are not detectable before 16-72 hr incubation (20) . We therefore performed a time-course study in which MCF-7 cells were exposed to E2 for increasing periods of time (0, 2, 8, 16, 24, and 48 hr). For almost all estrogen-responsive genes detected in the screening, including the four marker genes presented in this paper, the changes in gene expression were detectable within [2] [3] [4] [5] [6] [7] [8] hr, suggesting that they are primary effects of E2 (Figure 4) Tables 1 and 2 ). PCR amplification of cDNA synthesized from different RNA samples, it is important that the protocols do not introduce significant variation. In addition, because it is impossible to obtain completely identical loading on DDRT-PCR gels, it must be possible to normalize the lanes, according to either the background or to a constant band.
To test the consistency of the method, we performed three cDNA synthesis reactions from a single RNA preparation, followed by three PCR runs of each cDNA; the results for the pS2 primer set are shown in Figure  6A . The DDRT-PCR gel was scanned by phosphor imaging and the results normalized according to the back-ground just below the pS2 band ( Figure 6B ). This showed that the variation introduced by the cDNA synthesis and PCR was < 24 and 16%, respectively, and that the maximal variation between two samples was < 34%. These differences are representative of the variation we have observed among the hundreds of samples that have been analyzed; this variation is small as compared to the severalfold differences among samples treated with different concentrations ofestrogens.
To test the power of the normalization, two-thirds and one-third of the volume of the sample in lane 9 (sample C/3) were loaded separately ( Figure 6A, lanes 10, 11, and 12 ). After normalization, the pS2 values in these lanes were essentially identical, showing that normalization according to the background or a constant band can be used to normalize samples, even when the loaded amounts differ by 300% ( Figure 6B, lanes 10, 11, and 12) .
Identification of estrogenic chemicals. We used the four marker genes to estimate the estrogenicity of the following compounds: E2, ZA, DES, GS, NP, BisA, DBP, MC, ES, DDE, 4-OH-TAM, and ICI 182.780. The relative potencies of the tested compounds on the expression of the four genes are shown in Table 3 .
Induction ofpS2 mRNA expression. Induction of pS2 mRNA is a widely used indicator of estrogenicity (9, 11, 37) , and pS2 mRNA was detected several times in the screening. It is rapidly and strongly induced by estrogens; therefore, we selected pS2 as one of the marker genes. Because its expression is so strongly correlated to the level of estrogen, we routinely, as a first approach, test a compound for ability to induce the pS2 gene. Thus, for all test compounds, we assayed the induction of pS2 mRNA by DDRT-PCR (Figure 7 ) and quantitated the expression profiles by phosphor imaging (Figure 8) .
The expression level of pS2 mRNA was increased in a dose-dependent manner by all the tested estrogens; however, their potencies were very different. Based on their relative potency (Table 3) , the chemicals can be divided into three groups. Group 1 includes E2, ZA, and DES, which cause detectable increases in pS2 at 10-12 M-10-'1 M; Group 2 includes NP and GS, which induce pS2 at 103-to 104-fold higher concentrations (> 10-8 M); and Group 3 includes BisA, DDE, MC, ES, and DBP, which require 105-to 106-fold higher concentrations, relative to E2, to induce pS2 ( Figure 7, Figure  8 ). The high-potency estrogens in Group 1 (E2, ZA, and DES) cause a significantly greater quantitative change in the expression level of pS2 as compared to the environmental estrogens in Groups 2 and 3. For example, the expression level of pS2 is increased almost 25-fold after exposure to E2 (10-10 M), but less than 10-fold after exposure to DBP (104 M) ( Figure 7, Figure 8) .
A slight increase in the expression level of pS2 mRNA was also observed after exposure to high concentrations (> 10-7 M) of 4-OH-TAM ( Figure 7, Figure 8 ). 10-13 M (Figure 9 ), equivalent to, or even below, the dose required to induce pS2 mRNA expression ( Figure 7, Figure 8 ), whereas detectable induction of al-ACT required a 100-fold higher concentration (10`1 M) ( Figure 9 ). The other test compounds caused detectable changes in the expression levels of TGFI3 and MAO-A at doses similar to those required for pS2 induction, but for most chemicals, the concentrations required to induce al-ACT were 10-to 100-fold higher ( Figure 9 ). There are significant marker gene-dependent differences in the rank order of potencies of the test compounds (Table 3 ). For example, the potencies of E2, DES, and ZA were essentially identical on TGEF3, whereas the potency of ZA was almost 100-fold lower than the potency of E2 and DES on pS2, al-ACT, and MAO-A. Furthermore, NP and GS affected the expression levels of pS2 and TGF33 with similar potencies, whereas the potency of NP was almost 10-fold higher than the potency of GS on MAO-A; the potency of NP on al-ACTwas lower than that of GS (Table 3) .
The partial estrogen agonist 4-OH-TAM slightly increased expression levels of al-ACT and pS2 and reduced the expression level of MAO-A, suggesting that 4-OH-TAM acts as a partial agonist on these genes. In contrast, a high concentration of 4-OH-TAM slightly increased the expression of TGF[3 ( Figure 9 ), suggesting that it acts as an antagonist or a selective estrogen receptor modulator (SERM) on TGF133. Discussion
In this paper we demonstrate that the estrogenic activity of a chemical can be evaluated by assaying induction or repression of endogenous estrogen-regulated marker genes in human estrogen-dependent breast cancer cells. We also show that changes in gene expression levels quantitatively show a dose-response correlation. However, the endogenous gene expression assay is more time consuming and therefore less suited for large-scale screening of chemical compounds than other more simple in vitro assays.
The comparison of expression levels determined by PCR is a well-characterized The expression levels were quantitated by phosphor imaging scanning and normalized according to either a constant band or the background; this resulted in reproducible results and thus accurate estimates of estrogenic activity. This is shown by the small variation introduced in the cDNA synthesis and PCR (24 and 16%, respectively) , as compared to the many fold induction or repression resulting from exposure to the estrogenic compounds.
The Marker Genes
In this study, estrogenicity was determined by analyzing the expression levels of four marker genes: pS2, MAO-A, TGFf3, and al-ACT. Because the assay is based on endogenous gene expression, an arbitrary number of marker genes could, in principle, be included in the assay; the marker genes used in this study could be replaced by other estrogen-responsive genes such as the progesterone receptor.
PS2. The expression level of pS2 mRNA is a widely used indicator of estrogenicity, and the translation product of pS2 mRNA is also induced in MCF-7 cells in response to estrogen (37) . The 9 kDa encoded pS2 protein belongs to the trefoil family of peptides (48) (49) (50) . In vivo assays have been conducted because there seems to be a correlation between mood changes and estradiol levels that may be mediated through the activity of monoamine oxidases (51) (52) (53) . The activity and expression of MAO-A is inversely correlated both in vivo and in vitro to the estradiol concentration (49, 50) , which is similar to the regulation we have observed in MCF-7 cells. However, MAO genes may be induced by E2 in some tissues; Sarabia and Liehr (54) showed that expression of the MAO-B gene actually is induced by E2 in hamster kidneys.
The human MAO-A gene (accession no. AL020990; EMBL/EBI) contains several putative ERE sequences that could be responsible for the observed estrogen-dependent regulation of the MAO (55) , and cell-and tissue-typespecific expression has also been shown (56) . TGF33 expression is regulated by nonestrogenic compounds (57) , and it is probably necessary to include additional marker genes to be sure that only estrogens are detected.
Knabbe et al. (58) reported that TGFP3 inhibits the growth of MCF-7 cells and that secretion of TGF,3 is induced by antiestrogens. In our study, however, TGFP3 was only slightly increased after exposure to a high concentration of4-OH-TAM ( Figure 9 ).
The human TGFI3 sequence (accession no. X14885; EMBL/EBI) (59) contains a putative imperfect ERE 340 base pairs upstream from the transcription initiation site, which varies from the con-sensus ERE sequence at two positions, one in each halfpalindromic sequence (GGCCAGCAAC-TGCCC). Also, the two half-palindromic sequences are spaced by 5 base pairs, instead of 3. al-ACT. Estrogen-mediated induction has previously been described for the antiprotease al-ACT in human breast cancer cells (60, 61 (9, 11, 19) . Furthermore, because of its conversion to estrogens (63), 10-7 M testosterone had an estrogen-like effect on the expression of the marker genes, whereas 10-7 M progesterone had no effect on the expression levels (results not shown).
The four marker genes all responded strongly to the high-potency compounds (E2, DES, and ZA), but there were some differences in their potency, defined as the minimum concentration required to affect the expression of a marker gene. The potencies of E2 and DES were similar when assayed with pS2, TG113, and a(-ACT, whereas MAO-A seems to be more sensitive to E2 than to DES. The potency ofZA was equal to that of E2 and DES if assayed with TGFI3, but it was more than 10-fold lower than E2 and DES for the other three marker genes.
The potencies of the environmental estrogens were much lower than those of E2, DES, and ZA. As for the high-potency compounds, there were some differences in the relative potencies of the low-potency compounds on the four genes (Table 3) . For example, the potency of NP was equal to the potency of GS on two marker genes (pS2 and TGf143), but 10-to 100-fold higher and lower, respectively, when assayed with MAO-A and al-ACT
The relative potency of the compounds generally correlated with the relative change in expression level of the four genes, although this was most evident for pS2. For example, the expression level of pS2 was induced almost 25-fold after exposure to 10-10 M E2, approximately 16-fold after exposure to 102 M GS, and < 10-fold after exposure to i04 M DBP. For the other marker genes, this trend was less consistent. Fold induction/repression is very sensitive to the initial levels, and a slightly elevated level in the noninduced cells leads to significant variation in the fold change. Thus, the precise fold change varies between experiments, whereas the relative differences between compounds are maintained.
High concentrations (108_10-6 M) of TAM-OH seem to have small but detectable E2-like effects on the expression of MAO-A, pS2, and al-ACT, whereas similar concentrations may have a small stimulatory effect on TGF33. However, the required concentrations are so high that the effects may not be ER mediated; this is similar to what has been observed in SK-N-BE/SK-ER3 cells, in which the observed effects of tamoxifen apparently are independent of the presence of ERa. Unfortunately, the possible expression of ER,I has not been investigated in the SK-N-BE cells, although the lack of E2 response indicates that neither receptor subtype is present (48, 49) .
During the screening for estrogen-regulated genes, we detected several related genes that were consistently more sensitive to DES and ZA than to E2. These genes, however, show a time-dependent expression profile that is different from the majority of the identified E2-regulated genes; their expression was not affected before [8] [9] [10] [11] [12] [13] [14] [15] [16] hr exposure to the hormones (35) , whereas almost all other E2-regulated genes, including the four marker genes, were affected within 2-8 hr.
Future development. There are many aspects of the endogenous gene expression assay that could be improved. For example, we are assaying expression levels by radioactive incorporation during PCR, but fluorescent labels could be used instead, with the results analyzed on a DNA sequenator. In our hands, however, fluorescent labels reduce the sensitivity by 10-to 100-fold, although it may be possible to optimize both the PCR and the detection thereby obtaining a sensitivity that is similar to that of radioactivity-based assays. The Taq-Man technology (Perkin-Elmer) may be an atractive alternative. Another possibility is DNA chip technology (64, 65) . For example, construction of a chip with approximately 100 estrogen-regulated genes and a similar number of unaffected genes would allow almost complete automation of the assay. However, at present, the sensitivity of the chip technology limits its practical use; this will probably change, so DNA chip technology should be considered an alternative to PCR-based methods.
Endogenous gene expression assays could, in principle, be used to evaluate cellular responses to any compound, provided genes that respond to that dass of compounds have been identified. Thus, compounds acting through the androgen, thyroid, aromatic hydrocarbon, and other receptors could be identified by determining the expression levels of genes that are activated through these receptors. Assays to detect effects caused by activation of ER[ and the androgen receptor could be developed relatively easily from cell lines derived from the prostate.
Furthermore, endogenous gene expression assays are not limited to cell cultures because changes in expression levels of selected genes could be determined in different tissues from exposed animals. The number of animals required to assay thousands of compounds for their estrogenicity could be significantly reduced if gene expression-related end points could be established. For example, when the specific genes responsible for estrogen-induced uterine or breast growth have been identified and a relationship established between their expression and a disease, these genes could be assayed. An end point could then be fold induction of genes X and Y in tissue A and fold repression ofgene Z in tissue B.
Finally, an ultimate goal would be to develop an assay to directly analyze human samples, for example, derived from blood. This requires identification of genes expressed in blood cells that are affected by exposure to putative endocrine-disruptor compounds. We are currently analyzing blood samples for the expression of the E2-regulated genes that we indentified in the screening; preliminary results suggest that many of the genes which are regulated by E2 in MCF-7 cells are also expressed in various cells present in blood. However, we currently do not have information concerning possible E2 regulation in the blood, although reports in the literature suggested that there are E2-regulated genes in blood and that, for example, MAO-A may be a candidate for an E2-regulated gene which could be assayed in human blood samples. (48) .
